Whether vortioxetine has a utility as an adjuvant drug in the treatment of bipolar depression remains controversial. This study aimed to validate the effic
5 March 2026 in Journal of Clinical Laboratory Analysis
Background: Dyslipidemia was a hallmark of metabolic disturbances in coronary heart disease (CHD), metabolic syndrome (MetS), and nephrotic syndrome (NS), yet the specific lipid profile patterns characteristic of each disease remained insufficiently defined. Objective: This study aimed to clearly characterize and compare the qualitative features of lipid profiles across patients with CHD, MetS, and NS, and to identify key lipid markers associated with disease classification using multinomial logistic regression. Methods: A total of 180 patients were enrolled and classified into three groups (CHD, MetS, NS) based on established diagnostic criteria. 60 healthy controls were concurrently enrolled. Lipidomic profiles and additional laboratory parameters were measured using validated analytical methods. Multinomial logistic regression was used to evaluate the associations between lipid parameters and disease categories. Results: Lipid profile analysis revealed distinct qualitative trends across the disease groups. The CHD group demonstrated notably higher levels of TC and sdLDL, the MetS group exhibited prominent increases in TG and ApoE, while the NS group showed a broad and pronounced elevation across most measured lipid parameters. By contrast, the healthy control group consistently presented uniformly lower lipid levels. LASSO‐guided multinomial logistic regression identified TC, TG, ApoB, ApoE, and sdLDL‐C as independent predictors of disease classification. Conclusions: Distinct patterns of dyslipidemia were observed in CHD, MetS, and NS. TC and sdLDL‐C might serve as robust markers for CHD, while ApoB demonstrated disease‐specific variability with diagnostic potential. These findings underscored the importance of detailed lipid profiling for improved risk stratification and targeted management.
The prevalence of depressive disorders continues to increase, representing a leading contributor to global disability and disease burden. Although antidepressants remain the cornerstone of treatment, their variable efficacy and adverse effects have drawn increasing attention. Vascular homeostasis is tightly regulated by the dynamic balance between coagulation and fibrinolysis, processes essential for maintaining physiological integrity. Emerging evidence indicates that antidepressants, beyond their effects on mood and cognition, may modulate endothelial function, platelet activity, and the coagulation-fibrinolysis system through multiple biological pathways. These interactions suggest a previously underappreciated link between antidepressant therapy and vascular regulation. Elucidating the molecular mechanisms by which antidepressants influence vascular homeostasis may enhance understanding of the systemic pathophysiology of depression and inform safer, more individualized treatment strategies. This review systematically summarizes the effects of different classes of antidepressants on coagulation and fibrinolytic systems, with a focus on their molecular mechanisms and potential clinical implications.